Last reviewed · How we verify
Evaluation of Safety and Efficacy Evaluation Post Intravenous Infusion of Activated NK Cells in Recurrent and Refractory High-risk Neuroblastoma Patients
The goal of this clinical trial is to assess safety and efficacy of systemic injection of allogenic NK cells in patients with refractory/recurrent high-risk neuroblastoma. Is the injection of allogenic nk cells safe in patients with R/R high-risk neuroblastoma? Is the injection of allogenic nk cells effective in patients with R/R high-risk neuroblastoma? We will compare the NK cell administration group with a control group that receives conventional treatment to determine whether the intervention is safe and effective
Details
| Lead sponsor | Marzieh Ebrahimi |
|---|---|
| Phase | Phase 1 |
| Status | RECRUITING |
| Enrolment | 10 |
| Start date | 2024-11-10 |
| Completion | 2026-11 |
Conditions
- Neuroblastoma, Recurrent, Refractory
- Neuroblastoma (NB)
- Neuroblastoma in Children
Interventions
- Allogenic NK cells infusion
Primary outcomes
- NK Cell Infusion Safety — After each injection to next injection and 2 weeks after last injection
The safety of the treatment is assessed using the Common Terminology Criteria for Adverse Events (CTCAE) checklist.
Countries
Iran